抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3128人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852997, encodeId=f790185299e72, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌, objectType=article, longId=729651, objectId=592de2965133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=592de2965133, replyNumber=0, likeNumber=81, createdTime=2022-09-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=592de2965133, moduleTitle=Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=592de2965133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852867, encodeId=f5bf185286eb4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMC Cancer：白蛋白紫杉醇联合PD-1抑制剂信迪利单抗是晚期软组织肉瘤(STS)的有前景治疗方案, objectType=article, longId=294052, objectId=a3fb294052fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3fb294052fd, replyNumber=0, likeNumber=99, createdTime=2022-02-08, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3fb294052fd, moduleTitle=BMC Cancer：白蛋白紫杉醇联合PD-1抑制剂信迪利单抗是晚期软组织肉瘤(STS)的有前景治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3fb294052fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853028, encodeId=9d07185302848, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JGH: 长期质子泵抑制剂的使用与骨质疏松症和髋部骨折的风险, objectType=article, longId=735612, objectId=f276e3561217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f276e3561217, replyNumber=0, likeNumber=91, createdTime=2022-11-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f276e3561217, moduleTitle=JGH: 长期质子泵抑制剂的使用与骨质疏松症和髋部骨折的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f276e3561217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852839, encodeId=d2cb185283940, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JBC：在白血病细胞中靶向致癌酪氨酸磷酸酶SHP2的新型呋喃苯甲酰胺抑制剂的发现, objectType=article, longId=291879, objectId=d3a82918e9b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3a82918e9b0, replyNumber=0, likeNumber=132, createdTime=2022-11-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3a82918e9b0, moduleTitle=JBC：在白血病细胞中靶向致癌酪氨酸磷酸酶SHP2的新型呋喃苯甲酰胺抑制剂的发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3a82918e9b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853013, encodeId=e042185301315, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Radiology：免疫检查点抑制剂诱发心肌炎的心脏MRI特征及预后价值, objectType=article, longId=731452, objectId=2a5ae31452ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a5ae31452ed, replyNumber=0, likeNumber=87, createdTime=2023-05-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a5ae31452ed, moduleTitle=Radiology：免疫检查点抑制剂诱发心肌炎的心脏MRI特征及预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a5ae31452ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852780, encodeId=be421852e80c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果, objectType=article, longId=218574, objectId=67f02185e4be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67f02185e4be, replyNumber=0, likeNumber=73, createdTime=2021-11-26, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67f02185e4be, moduleTitle=KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67f02185e4be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852834, encodeId=1c8f1852834fe, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, objectType=article, longId=221813, objectId=789422181362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789422181362, replyNumber=0, likeNumber=98, createdTime=2022-07-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789422181362, moduleTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=789422181362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852925, encodeId=86c418529255d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Physiol Rep：FXa因子抑制剂艾多沙班可通过减少上皮间质转化和炎症反应来改善肾大部分切除术后的肾损伤, objectType=article, longId=301747, objectId=284b301e47e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=284b301e47e0, replyNumber=0, likeNumber=82, createdTime=2023-03-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=284b301e47e0, moduleTitle=Physiol Rep：FXa因子抑制剂艾多沙班可通过减少上皮间质转化和炎症反应来改善肾大部分切除术后的肾损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=284b301e47e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852843, encodeId=883318528437b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer：癌症患者COVID- 19灭活疫苗对血清转换的免疫检查点抑制剂的影响和Nomogram预测, objectType=article, longId=292196, objectId=04b42921962d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04b42921962d, replyNumber=0, likeNumber=58, createdTime=2022-08-14, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04b42921962d, moduleTitle=J Immunother Cancer：癌症患者COVID- 19灭活疫苗对血清转换的免疫检查点抑制剂的影响和Nomogram预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04b42921962d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852853, encodeId=9ffc185285342, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=293023, objectId=5fe32930236d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fe32930236d, replyNumber=0, likeNumber=42, createdTime=2022-07-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fe32930236d, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fe32930236d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852854, encodeId=6ed9185285464, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, objectType=article, longId=293110, objectId=00a32931103c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a32931103c, replyNumber=0, likeNumber=77, createdTime=2022-09-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a32931103c, moduleTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a32931103c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852824, encodeId=bab918528248b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Lymphoma Myeloma Leuk：接受免疫检查点抑制剂治疗的 AML 患者的感染并发症, objectType=article, longId=221212, objectId=7f77221212e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f77221212e6, replyNumber=0, likeNumber=95, createdTime=2022-09-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f77221212e6, moduleTitle=Clin Lymphoma Myeloma Leuk：接受免疫检查点抑制剂治疗的 AML 患者的感染并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f77221212e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852876, encodeId=5a3618528e651, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效, objectType=article, longId=295059, objectId=afe5295059f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe5295059f2, replyNumber=0, likeNumber=85, createdTime=2022-06-08, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe5295059f2, moduleTitle=Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe5295059f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852913, encodeId=02e21852913f1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JEADV：分泌型白细胞蛋白酶抑制剂调节银屑病中神经反射介导的皮肤屏障功能, objectType=article, longId=301121, objectId=51443011213c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51443011213c, replyNumber=0, likeNumber=89, createdTime=2022-05-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51443011213c, moduleTitle=JEADV：分泌型白细胞蛋白酶抑制剂调节银屑病中神经反射介导的皮肤屏障功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51443011213c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852763, encodeId=90cd1852e63b4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Respir Med：从磷酸二酯酶5抑制剂到利奥西呱转换治疗评估, objectType=article, longId=217879, objectId=49a121e879d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49a121e879d0, replyNumber=0, likeNumber=74, createdTime=2022-01-08, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49a121e879d0, moduleTitle=Lancet Respir Med：从磷酸二酯酶5抑制剂到利奥西呱转换治疗评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49a121e879d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852856, encodeId=8af618528565b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clinical Gastroenterology H: 纤溶酶原激活物抑制剂-1可以作为小儿嗜酸性粒细胞性食管炎食管功能变化的标志物, objectType=article, longId=292994, objectId=2735292994f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2735292994f2, replyNumber=0, likeNumber=66, createdTime=2022-06-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2735292994f2, moduleTitle=Clinical Gastroenterology H: 纤溶酶原激活物抑制剂-1可以作为小儿嗜酸性粒细胞性食管炎食管功能变化的标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2735292994f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853012, encodeId=d5c618530129a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=乳腺癌治疗领域首个免疫检查点抑制剂惨败：T药联合新辅助双妥+化疗未能改善早期乳腺癌pCR！, objectType=article, longId=731017, objectId=9cd7e310174d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cd7e310174d, replyNumber=0, likeNumber=105, createdTime=2023-05-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cd7e310174d, moduleTitle=乳腺癌治疗领域首个免疫检查点抑制剂惨败：T药联合新辅助双妥+化疗未能改善早期乳腺癌pCR！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cd7e310174d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852805, encodeId=025d18528056b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=FDA授予IL-5抑制剂Fasenra（贝那利珠单抗）快速通道资格，用于治疗嗜酸性粒细胞性胃炎（EG）, objectType=article, longId=220145, objectId=3588220145b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3588220145b0, replyNumber=0, likeNumber=87, createdTime=2021-12-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3588220145b0, moduleTitle=FDA授予IL-5抑制剂Fasenra（贝那利珠单抗）快速通道资格，用于治疗嗜酸性粒细胞性胃炎（EG）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3588220145b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852808, encodeId=214b185280878, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据, objectType=article, longId=220347, objectId=48aa22034ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48aa22034ed7, replyNumber=0, likeNumber=102, createdTime=2021-12-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48aa22034ed7, moduleTitle=JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48aa22034ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853020, encodeId=38441853020b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Oncology：关于肾移植受者免疫检查点抑制剂治疗的影响——一项多中心、单臂、1期研究, objectType=article, longId=732651, objectId=fb71e32651ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb71e32651ee, replyNumber=0, likeNumber=109, createdTime=2022-11-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb71e32651ee, moduleTitle=Lancet Oncology：关于肾移植受者免疫检查点抑制剂治疗的影响——一项多中心、单臂、1期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb71e32651ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌

2022-09-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMC Cancer：白蛋白紫杉醇联合PD-1抑制剂信迪利单抗是晚期软组织肉瘤(STS)的有前景治疗方案

2022-02-08

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JGH: 长期质子泵抑制剂的使用与骨质疏松症和髋部骨折的风险

2022-11-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JBC：在白血病细胞中靶向致癌酪氨酸磷酸酶SHP2的新型呋喃苯甲酰胺抑制剂的发现

2022-11-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Radiology：免疫检查点抑制剂诱发心肌炎的心脏MRI特征及预后价值

2023-05-17

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果

2021-11-26

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌

2022-07-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Physiol Rep：FXa因子抑制剂艾多沙班可通过减少上皮间质转化和炎症反应来改善肾大部分切除术后的肾损伤

2023-03-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer：癌症患者COVID- 19灭活疫苗对血清转换的免疫检查点抑制剂的影响和Nomogram预测

2022-08-14

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2022-07-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好

2022-09-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Lymphoma Myeloma Leuk：接受免疫检查点抑制剂治疗的 AML 患者的感染并发症

2022-09-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效

2022-06-08

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JEADV：分泌型白细胞蛋白酶抑制剂调节银屑病中神经反射介导的皮肤屏障功能

2022-05-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Respir Med：从磷酸二酯酶5抑制剂到利奥西呱转换治疗评估

2022-01-08

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clinical Gastroenterology H: 纤溶酶原激活物抑制剂-1可以作为小儿嗜酸性粒细胞性食管炎食管功能变化的标志物

2022-06-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

乳腺癌治疗领域首个免疫检查点抑制剂惨败：T药联合新辅助双妥+化疗未能改善早期乳腺癌pCR！

2023-05-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

FDA授予IL-5抑制剂Fasenra（贝那利珠单抗）快速通道资格，用于治疗嗜酸性粒细胞性胃炎（EG）

2021-12-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据

2021-12-20

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Oncology：关于肾移植受者免疫检查点抑制剂治疗的影响——一项多中心、单臂、1期研究

2022-11-20

科室
- - 订阅+
  - 更多科室
工具
服务